HIV/AIDS: a look at the problem

DOI: https://doi.org/10.29296/25877305-2021-02-07
Download full text PDF
Issue: 
2
Year: 
2021

Professor K. Amlaev, MD Stavropol State Medical University

The article in the format of a mini-lecture is devoted to the problem of HIV infection. Data on the history of the virus in the 20s of the last century are presented. The mechanisms of infection and the risks of infection with the virus through various actions are considered. The main modern approaches to the prevention and treatment of the disease are briefly described, and the concept of the AIDS stage is given.
Keywords: 
infectious disease
HIV
AIDS
medical prevention

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Sharp P.M., Hahn B.H. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011; 1 (1): a006841. DOI: 10.1101/cshperspect.a006841
  2. Hymes K.B., Cheung T., Greene J.B. et al. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet. 1981; 2 (8247): 598–600. DOI: 10.1016/s0140-6736(81)92740-9
  3. Masur H., Michelis M.A., Greene J.B. et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981; 305 (24): 1431–8. DOI: 10.1056/NEJM198112103052402
  4. Piot P., Quinn T.C., Taelman H. et al. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet. 1984; 2 (8394): 65–9. DOI: 10.1016/s0140-6736(84)90241-1
  5. Van de Perre P., Rouvroy D., Lepage P. et al. Acquired immunodeficiency syndrome in Rwanda. Lancet. 1984; 2 (8394): 62–5. DOI: 10.1016/s0140-6736(84)90240-x
  6. Faria N.R., Rambaut A., Suchard M.A. et al. HIV Epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science. 2014; 346 (6205): 56–61. DOI: 10.1126/science.1256739
  7. Smith D.M., Richman D.D., Little S.J. HIV superinfection. J Infect Dis. 2005; 192 (3): 438–44. DOI: 10.1086/431682
  8. UNAIDS (2015). AIDS by the numbers. Available at: http://www.unaids.org/en/resources/documents/2015/AIDS_by_the_numbers_2015 [Accessed 15.06.2020].
  9. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach (2013 version). Geneva, Switzerland: WHO Press; 2013.
  10. World Health Organization. Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015. URL: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/
  11. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, second edition, June 2016. URL: http://www.who.int/hiv/pub/arv/arv-2016/en/
  12. UNAIDS (2013). HIV in Asia and the Pacific. Available at: http://www.unaids.org/en/resources/documents/2013/20131119_HIV-Asia-Pacific
  13. Saravanan S., Velu V., Kumarasamy N. et al. Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India. World J Gastroenterol. 2007; 13 (37): 5015–20. DOI: 10.3748/wjg.v13.i37.5015
  14. Khalsa J.H., Elkashef A. Interventions for HIV and hepatitis C virus infections in recreational drug users. Clin Infect Dis. 2010; 50 (11): 1505–11. DOI: 10.1086/652447
  15. Becerra J.C., Bildstein L.S., Gach J.S. Recent Insights into the HIV/AIDS Pandemic. Microbial Cell. 2016; 3 (9): 451–75. DOI: 10.15698/mic2016.09.529
  16. Grulich A.E., Zablotska I. Commentary: probability of HIV transmission through anal intercourse. Int J Epidemiol. 2010; 39 (4): 1064–5. DOI: 10.1093/ije/dyq101
  17. Boily M.C., Baggaley R.F., Wang L. et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009; 9 (2): 118–29. DOI: 10.1016/S1473-3099(09)70021-0
  18. Keele B.F., Estes J.D. Barriers to mucosal transmission of immunodeficiency viruses. Blood. 2011; 118 (4): 839–46. DOI: 10.1182/blood-2010-12-325860
  19. Patel P., Borkowf C.B., Brooks J.T. et al. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014; 28 (10): 1509–19. DOI: 10.1097/QAD.0000000000000298
  20. Quinn T.C., Wawer M.J., Sewankambo N. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342 (13): 921–9. DOI: 10.1056/NEJM200003303421303
  21. Baeten J.M., Kahle E., Lingappa J.R. et al. Partners in Prevention HSVHIVTST Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011; 3 (77): 77ra29. DOI: 10.1126/scitranslmed.3001888
  22. Galvin S.R., Cohen M.S. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004; 2 (1): 33–42. DOI: 10.1038/nrmicro794
  23. Laga M., Piot P. Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. AIDS. 2012; 26 (10): 1223–9. DOI: 10.1097/QAD.0b013e32835462b8
  24. Marrazzo J.M., Cates W. Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis. 2011; 53 (Suppl. 3): S64–78. DOI: 10.1093/cid/cir695
  25. Chang L.W., Serwadda D., Quinn T.C. et al. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis. 2013; 13 (1): 65–76. DOI: 10.1016/S1473-3099(12)70273-6
  26. Volk J.E., Marcus J.L., Phengrasamy T. et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015; 61 (10): 1601–3. DOI: 10.1093/cid/civ778
  27. Coffin J., Swanstrom R. HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med. 2013; 3 (1): a012526. DOI: 10.1101/cshperspect.a012526
  28. Stacey A.R., Norris P.J., Qin L. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009; 83 (8): 3719–33. DOI: 10.1128/JVI.01844-08
  29. Pincus J.M., Crosby S.S., Losina E. et al. Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis. 2003; 37 (12): 1699–704. DOI: 10.1086/379772
  30. Tokman S., Huang L. Evaluation of respiratory disease. Clin Chest Med. 2013; 34 (2): 191–204. DOI: 10.1016/j.ccm.2013.02.005
  31. Janoff E.N., Breiman R.F., Daley C.L. et al. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med. 1992; 117 (4): 314–24. DOI: 10.7326/0003-4819-117-4-314
  32. Hirschtick R.E., Glassroth J., Jordan M.C. et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med. 1995; 333 (13): 845–51. DOI: 10.1056/NEJM199509283331305
  33. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010; 85 (1): 1–18. DOI: 10.1016/j.antiviral.2009.10.002
  34. Kulpa D.A., Chomont N. HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad. 2015; 1 (2): 59–66.
  35. Guerrero M.L.F., Rivas P., Molina M. et al. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clin Infect Dis. 2005; 41 (3): 390–4. DOI: 10.1086/431487
  36. Ford N., Calmy A., Hurst S. When to start antiretroviral therapy in resource-limited settings: a human rights analysis. BMC Int Health Hum Rights. 2010; 10: 6. DOI: 10.1186/1472-698X-10-6
  37. Deeks S.G. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies. Clin Infect Dis. 2000; 30: S177–S184. DOI: 10.1086/313855
  38. Lee P.K., Kieffer T.L., Siliciano R.F. et al. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother. 2006; 57 (5): 803–5. DOI: 10.1093/jac/dkl092
  39. Bertozzi S., Padian N.S., Wegbreit J. et al. HIV/AIDS Prevention and Treatment. Disease Control Priorities in Developing Countries. 2nd Ed. 2006; p. 331–69.
  40. Volk J.E., Marcus J.L., Phengrasamy T. et al. No New HIV Infections with Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis. 2015; 61 (10): 1601–3. DOI: 10.1093/cid/civ778
  41. Sabin C.A., Phillips A.N. Should HIV therapy be started at a CD4 cell count above 350 cells/mu l in asymptomatic HIV-1-infected patients? Curr Opin Infect Dis. 2009; 22 (2): 191–7. DOI: 10.1097/QCO.0b013e328326cd34
  42. Jain V., Deeks S.G. When to start antiretroviral therapy. Curr HIV/AIDS Rep. 2010; 7 (2): 60–8. DOI: 10.1007/s11904-010-0044-6
  43. Franco R.A., Saag M.S. When to start antiretroviral therapy: as soon as possible. BMC Med. 2013; 11: 147. DOI: 10.1186/1741-7015-11-148
  44. Lundgren J.D., Babiker A.G., Gordin F.M. et al. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med. 2013; 11: 148. https://doi.org/10.1186/1741-7015-11-148
  45. Group TAS: Danel C., Moh R., Gabillard D. et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373 (9): 808–22. DOI: 10.1056/NEJMoa1507198
  46. Nachega J.B., Parienti J.J., Uthman O.A. et al. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clin Infect Dis. 2014; 58 (9): 1297–307. DOI: 10.1093/cid/ciu046
  47. May M.T., Gompels M., Delpech V. et al. Study UKCHC. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014; 28 (8): 1193–202. DOI: 10.1097/QAD.0000000000000243
  48. Liu C., Ma X., Liu B. et al. HIV-1 functional cure: will the dream come true? BMC Med. 2015; 13: 284. DOI: 10.1186/s12916-015-0517-y